Prostate cancer

Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires

Retrieved on: 
Friday, February 16, 2024

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice President of Clinical Strategy and Investments.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice President of Clinical Strategy and Investments.
  • “Rich and Karen strengthen our commercial and clinical bench, better positioning us to capitalize on this exciting period in the life sciences industry,” said Todd Davis, CEO of Ligand.
  • “These appointments are the latest in Ligand’s initiative to enhance and scale our deal capabilities by selectively adding new talent.
  • He also served as co-head of the healthcare team at Hayfin Capital Management LLP, which deployed $1.4 billion in capital over four years.

Nonfiction Legal Drama INTENTIONAL DECEIT Chronicles Doctor’s Wrongful Incarceration

Retrieved on: 
Thursday, February 15, 2024

This true-to-life legal drama points out holes in the justice system that not only threatened a man’s livelihood but also denied him the ability to use his patented life-saving procedure to cure men with prostate cancer.

Key Points: 
  • This true-to-life legal drama points out holes in the justice system that not only threatened a man’s livelihood but also denied him the ability to use his patented life-saving procedure to cure men with prostate cancer.
  • Now, Dr. Wheeler is denied the ability to perform his patented and life-saving procedure on patients with prostate cancer.
  • Intentional Deceit will be of special interest to men who are affected by prostate cancer and curious about Dr. Wheeler’s life-saving method for curing patients without surgery to remove the prostate gland.
  • Readers interested in stories about flaws in the justice system may find Intentional Deceit a sobering call for action and change.

Argonne Uncovers Insights About Prostate Cancer Risk and Genetic Ancestry

Retrieved on: 
Thursday, February 15, 2024

A recent study involving scientists from the U.S. Department of Energy’s (DOE) Argonne National Laboratory has uncovered insights into the prostate cancer risks of people from a variety of genetic ancestries.

Key Points: 
  • A recent study involving scientists from the U.S. Department of Energy’s (DOE) Argonne National Laboratory has uncovered insights into the prostate cancer risks of people from a variety of genetic ancestries.
  • Prostate cancer is the most frequently diagnosed non-skin cancer globally, and as such, it is a problem that affects the entire human population.
  • To understand the likelihood of an individual or population developing prostate cancer, researchers create what is known as a Genetic Risk Score (GRS).
  • This work was centered around a desire to understand the genetic makeup that increases risks for diseases like prostate cancer.

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Retrieved on: 
Tuesday, February 13, 2024

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

Key Points: 
  • COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.
  • To strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024.
  • By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025.
  • Under the terms of the deal, Curasight is responsible for development until regulatory approval with Curium responsible for manufacturing and commercialisation.

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Retrieved on: 
Tuesday, February 13, 2024

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

Key Points: 
  • COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.
  • To strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024.
  • By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025.
  • Under the terms of the deal, Curasight is responsible for development until regulatory approval with Curium responsible for manufacturing and commercialisation.

Plant-Based Diet Tied to Improved Sexual Health in Men Treated for Prostate Cancer

Retrieved on: 
Tuesday, February 13, 2024

Chan School of Public Health, the analysis of more than 3,500 men with prostate cancer explored whether eating a more plant-based diet was associated with quality-of-life issues that often arise after treatment.

Key Points: 
  • Chan School of Public Health, the analysis of more than 3,500 men with prostate cancer explored whether eating a more plant-based diet was associated with quality-of-life issues that often arise after treatment.
  • Similarly, the results revealed up to 14% better scores for urinary health, with fewer instances of incontinence, obstruction, and irritation.
  • Prostate cancer is among the most common and deadliest forms of cancer among American men, according to the U.S. Centers for Disease Control and Prevention.
  • Funding for the study was provided by National Institutes of Health grant U01CA167552, New York State Department of Health, Tricia and Michael Berns, and the Prostate Cancer Foundation.

Prostate Cancer Prevention and Treatment Technologies: Comprehensive Global Market Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024

The "Prevention and Treatment of Prostate Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prevention and Treatment of Prostate Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The global market for prostate cancer care reached $35.3 billion in 2022.
  • The global market for prostate cancer screening and detection is projected to grow at a CAGR of 5.8% to reach $19.8 billion by the end of 2028.
  • Continued incidence of prostate cancer, the world's growing elderly population, and increasing therapeutic innovations are key driving factors in the market for prostate cancer drugs.

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

Retrieved on: 
Monday, February 12, 2024

NEW HAVEN, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of BXCL701 in combination with a CPI for the treatment of patients with metastatic small cell neuroendocrine prostate cancer (SCNC) with progression on chemotherapy and no evidence of microsatellite instability. The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions, fill unmet medical needs, and bring promising medicines to patients more quickly. Therapies granted this designation are given the opportunity for more frequent interactions with the FDA, a rolling review, and potential eligibility for accelerated approval and priority review. 

Key Points: 
  • The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions, fill unmet medical needs, and bring promising medicines to patients more quickly.
  • Therapies granted this designation are given the opportunity for more frequent interactions with the FDA, a rolling review, and potential eligibility for accelerated approval and priority review.
  • At the same time, it further validates the unique AI-based drug re-innovation approach that we used to discover this asset,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics.
  • “We are encouraged by the potential of BXCL701, which has demonstrated clinical proof of concept in both SCNC and adenocarcinoma.

SK Life Science Labs Experts Unveil Latest Scientific Findings at Keystone Symposia on Epigenetic Mechanisms and Cancer Treatment, and the 2nd Annual Molecular Glue Drug Development Summit

Retrieved on: 
Thursday, February 8, 2024

Helai Mohammad, Ph.D., VP and Head of Biology, and one of the expert scientists leading SK Life Science Labs, whose leadership team together have more than 120 years of drug discovery and development experience, was invited to present at the Keystone Symposia.

Key Points: 
  • Helai Mohammad, Ph.D., VP and Head of Biology, and one of the expert scientists leading SK Life Science Labs, whose leadership team together have more than 120 years of drug discovery and development experience, was invited to present at the Keystone Symposia.
  • Dr. Mohammad showcased SK Life Science Labs’ most recent data and its novel approach to the degradation of epigenetic machinery for the treatment of cancer.
  • “The pre-clinical data we presented at the Keystone Symposia broadens our understanding of how targeted protein degradation can be leveraged to achieve selectivity and, thereby, increase efficacy,” said Dr. Mohammad.
  • For more information about SK Life Science Labs and to review these and other scientific presentations, please visit our website at www.sklslabs.com/news-media .

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

Retrieved on: 
Thursday, February 8, 2024

Dr. Cesano succeeds Dr. Kenneth Hillan, who will step down effective today after a successful 7-year tenure as a director of Zymeworks.

Key Points: 
  • Dr. Cesano succeeds Dr. Kenneth Hillan, who will step down effective today after a successful 7-year tenure as a director of Zymeworks.
  • “Zymeworks is honored to welcome Dr. Cesano to our board of directors,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
  • She joins three other new directors appointed in 2023: Mr. Derek Miller, Mr. Carlos Campoy, and Dr. Nancy Davidson.”
    “The Zymeworks board of directors is sincerely grateful to Dr. Hillan for his dedicated service and significant contributions to the board.
  • Dr. Cesano was also appointed to serve as a member of the research and development committee and nominating and corporate governance committee of the board of directors.